logo
科言猫学术研究的AI总结
language
手机端手机端
  • Phone Feature微信小程序
简体中文简体中文
notice消息通知
博客博客
arrow
A

Akihiro Bessho

japanese red cross okayama hospital
H指数:24
被引数:2,017

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Plasma metabolomic profiling to predict durable response and survival with afatinib in EGFR-mutated non-small cell lung cancer: A prospective, multicenter, observational biomarker study

血浆代谢组学分析预测EGFR突变非小细胞肺癌患者接受阿法替尼治疗后的持久缓解和生存：一项前瞻性、多中心、观察性生物标志物研究

Therapeutic Advances in Medical Oncology
IF4.2
2026-11-030
PRE
Takeshi Honda; Kei Morikawa; Saori Takata; Hisashi Tanaka; Hidetoshi Itani; Kazuya Horiuchi; Ichiro Kawada; Hideyuki Nakagawa; Yoshiro Nakahara; Yoshitaka Seki; Akihiro Bessho; Nobumasa Takahashi; Kentaro Hayashi; Takeo Endo; Kiyoshi Takeyama; Toshiya Maekura; Nagio Takigawa; Akikazu Kawase; Makoto Endoh; Kenji Nemoto; Kazuma Kishi; Tomoko Fukuuchi; Yuko Iwasaki; Kenzo Soejima; Yusuke Okuma; Akira Togashi; Koji Ueda; Kenichi Yoshimura; Noriyuki Matsutani; Nobuhiko Seki; Daisuke Saigusa
Durvalumab plus irinotecan + cisplatin for untreated extensive-stage small cell lung cancer: REBORN, phase II study (WJOG13520L)

度伐利尤单抗联合伊立替康+顺铂用于未经治疗的广泛期小细胞肺癌：REBORN，II期研究（WJOG13520L）

Lung Cancer
IF4.4
2025-06-290
OA
Motoko Tachihara; Hiroyasu Shoda; Yuki Akazawa; Takayo Ota; Masahide Oki; Yuki Sato; Shunichi Sugawara; Satoshi Ikeda; Toshihide Yokoyama; Hiroyasu Kaneda; Shoichi Itoh; Akihiro Bessho; Nobuyuki Katakami; Satoshi Morita; Kazuhiko Nakagawa; Isamu Okamoto; Nobuyuki Yamamoto
Plasma cell-free DNA methylation profile before afatinib treatment is associated with progression-free and overall survival of patients with epidermal growth factor receptor gene mutation-positive non-small cell lung cancer

afatinib治疗前的血浆游离DNA甲基化谱与表皮生长因子受体基因突变阳性非小细胞肺癌患者的无进展生存期和总生存期相关

CLINICAL EPIGENETICS
IF4.4
2025-04-250
OA
Fujimoto, Mao; Yasuda, Hiroyuki; Arai, Eri; Nakajima, Makoto; Takata, Saori; Morikawa, Kei; Tanaka, Hisashi; Itani, Hidetoshi; Honda, Takeshi; Horiuchi, Kazuya; Watanabe, Kageaki; Nakagawa, Hideyuki; Nakahara, Yoshiro; Seki, Yoshitaka; Bessho, Akihiro; Takahashi, Nobumasa; Hayashi, Kentaro; Endo, Takeo; Takeyama, Kiyoshi; Maekura, Toshiya; Takigawa, Nagio; Kawase, Akikazu; Endoh, Makoto; Nemoto, Kenji; Kishi, Kazuma; Soejima, Kenzo; Okuma, Yusuke; Togashi, Akira; Matsutani, Noriyuki; Seki, Nobuhiko; Kanai, Yae
Five-year outcomes with gefitinib induction and chemoradiotherapy in EGFR-mutant stage III non-small-cell lung cancer: LOGIK0902/OLCSG0905 phase II study

吉非替尼诱导联合化放疗在EGFR突变型III期非小细胞肺癌中的五年结果：LOGIK0902/OLCSG0905 II期研究

international journal of oncology
IF2.8
2025-02-050
OA
Hotta, Katsuyuki; Saeki, Sho; Sakata, Shinya; Yamaguchi, Masafumi; Harada, Daijiro; Bessho, Akihiro; Tanaka, Kentaro; Inoue, Koji; Inoue, Koji; Gemba, Kenichi; Kubo, Toshio; Sato, Akiko; Ichihara, Eiki; Watanabe, Hiromi; Kishimoto, Junji; Shioyama, Yoshiyuki; Katsui, Kuniaki; Sugio, Kenji; Kiura, Katsuyuki
A phase II study of irinotecan-cisplatin plus durvalumab for untreated extensive-stage small cell lung cancer (WJOG13520L, REBORN trial)

伊立替康-顺铂联合度伐利尤单抗治疗初治广泛期小细胞肺癌的II期研究（WJOG13520L，REBORN试验）

ANNALS OF ONCOLOGY
IF65.4
2024-12-010
PRE
Tachihara, M.; Shoda, H.; Akazawa, Y.; Ota, T.; Oki, M.; Sato, Y.; Sugawara, S.; Ikeda, S.; Yokoyama, T.; Kaneda, H.; Itoh, S.; Bessho, A.; Katakami, N.; Morita, S.; Nakagawa, K.; Okamoto, I.; Yamamoto, N.
Significance of micro-EGFR T790M mutations on EGFR-tyrosine kinase inhibitor efficacy in non-small cell lung cancer
SCIENTIFIC REPORTS
IF3.9
2023-11-132
OAAI
Masuda, Takeshi; Miura, Satoru; Sato, Yuki; Tachihara, Motoko; Bessho, Akihiro; Nakamura, Atsushi; Miyawaki, Taichi; Yoshimine, Kohei; Mori, Masahide; Shiraishi, Hideaki; Hamai, Kosuke; Haratani, Koji; Maeda, Sumiko; Tabata, Eriko; Kitagawa, Chiyoe; Tanizaki, Junko; Imai, Takumi; Nogami, Shohei; Yamamoto, Nobuyuki; Nakagawa, Kazuhiko; Hattori, Noboru
Prospective exosome-focused translational research for afatinib (EXTRA) study of patients with nonsmall cell lung cancer harboring EGFR mutation: an observational clinical study
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2023-06-051
OAAI
Takata, Saori; Morikawa, Kei; Tanaka, Hisashi; Itani, Hidetoshi; Ishihara, Masashi; Horiuchi, Kazuya; Kato, Yasuhiro; Ikemura, Shinnosuke; Nakagawa, Hideyuki; Nakahara, Yoshiro; Seki, Yoshitaka; Bessho, Akihiro; Takahashi, Nobumasa; Hayashi, Kentaro; Endo, Takeo; Takeyama, Kiyoshi; Maekura, Toshiya; Takigawa, Nagio; Kawase, Akikazu; Endoh, Makoto; Nemoto, Kenji; Kishi, Kazuma; Soejima, Kenzo; Okuma, Yusuke; Yoshimura, Kenichi; Saigusa, Daisuke; Kanai, Yae; Ueda, Koji; Togashi, Akira; Matsutani, Noriyuki; Seki, Nobuhiko
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study): primary analysis
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2022-12-183
OAAI
Tanaka, Hisashi; Tanzawa, Shigeru; Misumi, Toshihiro; Makiguchi, Tomonori; Inaba, Megumi; Honda, Takeshi; Nakamura, Junya; Inoue, Koji; Kishikawa, Takayuki; Nakashima, Masanao; Fujiwara, Keiichi; Kohyama, Tadashi; Ishida, Hiroo; Kuyama, Shoichi; Miyazawa, Naoki; Nakamura, Tomomi; Miyawaki, Hiroshi; Oda, Naohiro; Ishikawa, Nobuhisa; Morinaga, Ryotaro; Kusaka, Kei; Fujimoto, Nobukazu; Fukuda, Yasushi; Yasugi, Masayuki; Tsuda, Takeshi; Ushijima, Sunao; Shibata, Kazuhiko; Shibayama, Takuo; Bessho, Akihiro; Kaira, Kyoichi; Shiraishi, Kenshiro; Matsutani, Noriyuki; Seki, Nobuhiko
Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2022-07-291
OAAI
Tanzawa, Shigeru; Makiguchi, Tomonori; Tasaka, Sadatomo; Inaba, Megumi; Ochiai, Ryosuke; Nakamura, Junya; Inoue, Koji; Kishikawa, Takayuki; Nakashima, Masanao; Fujiwara, Keiichi; Kohyama, Tadashi; Ishida, Hiroo; Kuyama, Shoichi; Miyazawa, Naoki; Nakamura, Tomomi; Miyawaki, Hiroshi; Oda, Naohiro; Ishikawa, Nobuhisa; Morinaga, Ryotaro; Kusaka, Kei; Miyamoto, Yosuke; Yokoyama, Toshihide; Matsumoto, Chiaki; Tsuda, Takeshi; Ushijima, Sunao; Shibata, Kazuhiko; Shibayama, Takuo; Bessho, Akihiro; Kaira, Kyoichi; Misumi, Toshihiro; Shiraishi, Kenshiro; Matsutani, Noriyuki; Seki, Nobuhiko
Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study
EUROPEAN JOURNAL OF CANCER
IF7.1
2021-03-0118
PREAI
Ito, Kentaro; Yamanaka, Takeharu; Hayashi, Hidetoshi; Hattori, Yoshihiro; Nishino, Kazumi; Kobayashi, Haruki; Oya, Yuko; Yokoyama, Toshihide; Seto, Takashi; Azuma, Koichi; Fukui, Tomoya; Kozuki, Toshiyuki; Nakamura, Atsushi; Tanaka, Kentaro; Hirano, Katsuya; Yokoi, Takashi; Daga, Haruko; Sakata, Shinya; Fujimoto, Daichi; Mori, Masahide; Maeno, Ken; Aoki, Takuya; Tamura, Atsuhisa; Miura, Satoru; Watanabe, Satoshi; Akamatsu, Hiroaki; Hataji, Osamu; Suzuki, Kensuke; Hontsu, Shigeto; Azuma, Koji; Bessho, Akihiro; Kubo, Akihito; Okuno, Motoyasu; Nakagawa, Kazuhiko; Yamamoto, Nobuyuki
A phase II study of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small-cell lung cancer in Japan (SAMURAI study)
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
IF4.2
2021-02-272
OAAI
Tanzawa, Shigeru; Ushijima, Sunao; Shibata, Kazuhiko; Shibayama, Takuo; Bessho, Akihiro; Kaira, Kyoichi; Misumi, Toshihiro; Shiraishi, Kenshiro; Matsutani, Noriyuki; Tanaka, Hisashi; Inaba, Megumi; Haruyama, Terunobu; Nakamura, Junya; Kishikawa, Takayuki; Nakashima, Masanao; Iwasa, Keiichi; Fujiwara, Keiichi; Kohyama, Tadashi; Kuyama, Shoichi; Miyazawa, Naoki; Nakamura, Tomomi; Miyawaki, Hiroshi; Ishida, Hiroo; Oda, Naohiro; Ishikawa, Nobuhisa; Morinaga, Ryotaro; Kusaka, Kei; Fujimoto, Nobukazu; Yokoyama, Toshihide; Gemba, Kenichi; Tsuda, Takeshi; Nakagawa, Hideyuki; Ono, Hirotaka; Shimizu, Tetsuo; Nakamura, Morio; Kusumoto, Sojiro; Hayashi, Ryuji; Shirasaki, Hiroki; Ochi, Nobuaki; Aoe, Keisuke; Kanaji, Nobuhiro; Kashiwabara, Kosuke; Inoue, Hiroshi; Seki, Nobuhiko
Phase II study of amrubicin plus erlotinib in previously treated, advanced non-small cell lung cancer with wild-type epidermal growth factor receptor (TORG1320)
INVESTIGATIONAL NEW DRUGS
IF2.7
2020-11-070
PREAI
Otani, Sakiko; Sasaki, Jiichiro; Nakahara, Yoshiro; Fukui, Tomoya; Igawa, Satoshi; Naoki, Katsuhiko; Bessho, Akihiro; Hosokawa, Shinobu; Fukamatsu, Nobuaki; Nakamura, Yukiko; Kasai, Takashi; Sugiyama, Tomohide; Tokito, Takaaki; Seki, Nobuhiko; Hamada, Akinobu; Okamoto, Hiroaki; Masuda, Noriyuki
A randomized phase 3 study of maintenance therapy with S-1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L)
CANCER
IF5.1
2020-06-023
OAAI
Tanaka, Kaoru; Morita, Satoshi; Ando, Masahiko; Yokoyama, Takuma; Nakamura, Atsushi; Yoshioka, Hiroshige; Ishiguro, Takashi; Miura, Satoru; Toyozawa, Ryo; Oguri, Tetsuya; Daga, Haruko; Ko, Ryo; Bessho, Akihiro; Tachihara, Motoko; Iwamoto, Yasuo; Hirano, Katsuya; Nakanishi, Yoichi; Nakagawa, Kazuhiko; Yamamoto, Nobuyuki; Okamoto, Isamu
Open-label, multicenter, randomized phase II study on docetaxel plus bevacizumab or pemetrexed plus bevacizumab for treatment of elderly (aged ≥75 years) patients with previously untreated advanced non-squamous non-small cell lung cancer: TORG1323
TRANSLATIONAL LUNG CANCER RESEARCH
IF3.5
2020-06-015
OAAI
Kozuki, Toshiyuki; Nogami, Naoyuki; Hataji, Osamu; Tsunezuka, Yoshio; Seki, Nobuhiko; Harada, Toshiyuki; Fujimoto, Nobukazu; Bessho, Akihiro; Takamura, Kei; Takahashi, Kazuhisa; Satouchi, Miyako; Kato, Terufumi; Shukuya, Takehito; Yamashita, Natsumi; Okamoto, Hiroaki; Shinkai, Tetsu

研究方向

暂未获取到该数据
K
Katsuyuki Kiura
H 指数:64论文数:1,029被引数:1.7万
K
Katsuyuki Hotta
H 指数:52论文数:649被引数:3.1万
N
Nagio Takigawa
H 指数:45论文数:566被引数:1.6万
K
Koji Inoue
H 指数:35论文数:299被引数:3,980
N
Nobuhiko Seki
H 指数:24论文数:184被引数:5,924
N
Noriyuki Matsutani
H 指数:21论文数:128被引数:1,651
K
Kenichi Gemba
H 指数:24论文数:120被引数:1,556
N
Nobuhisa Ishikawa
H 指数:43论文数:285被引数:6,943
N
Nobuyuki Yamamoto
H 指数:73论文数:1,055被引数:2.9万
H
Hisashi Tanaka
H 指数:19论文数:167被引数:1,140